Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male patients ranging from 25 to 65 years.~2. Type 1 or type 2 diabetic patients with a personal history of diabetes ≥ 5 years.~3. History of chronic erectile dysfunction for at least six months.~4. HbA1c ≤ 10%.~5. Baseline International Index of Erectile Function (IIEF) score of \< 26.~6. Not interested or able to use Phosphodiesterase type 5 inhibitor (PDE-5i) drug therapy and willing to forgo these treatments for the first 6 month period following study treatment.~7. Body mass index between 20 -30.~8. Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.~Exclusion Criteria:~1. Untreated hypogonadism or low serum total testosterone \< 200 ng/dl.~2. Current urinary tract or bladder infection.~3. Any medical evidence of any infectious disease.~4. Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history of priapism.~5. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.~6. Current or previous malignancy.~7. Patients with primary hyperlipidemia.~8. Use of any non study treatment for erectile dysfunction within 4 weeks of study treatment.~9. Lack of willingness to continue through 6 months after study treatment.~10. Any previous penile implant or penile vascular surgery.~11. Uncontrolled hypertension or hypotension (systolic blood pressure \> 170 or \< 90 mm Hg, and diastolic blood pressure \> 100 or \< 50 mm Hg).~12. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.~13. Bleeding or clotting disorder, use of anticoagulant therapy.~14. Lab values for complete blood count, prothrombin time/ partial thromboplastin time/international randomized ratio (PT/PTT/INR), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine falling outside the normal lab values.~15. Systemic autoimmune disorder.~16. Significant active systemic or localized infection.~17. Receiving immunosuppressant medications.~18. HbA1c \> 10%.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- autologous mesenchymal stem cells (Type: EXPERIMENTAL): Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients

Based on this trial design, predict the completion outcome and termination type (if applicable).